The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications
Open Access
- 10 June 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in The European Journal of Health Economics
- Vol. 13 (6), 723-740
- https://doi.org/10.1007/s10198-011-0326-y
Abstract
The objective of this study was to evaluate the methodological characteristics of cost-effectiveness evaluations carried out in Spain, since 1990, which include LYG as an outcome to measure the incremental cost-effectiveness ratio. METHODS: A systematic review of published studies was conducted describing their characteristics and methodological quality. We analyse the cost per LYG results in relation with a commonly accepted Spanish cost-effectiveness threshold and the possible relation with the cost per quality adjusted life year (QALY) gained when they both were calculated for the same economic evaluation. RESULTS: A total of 62 economic evaluations fulfilled the selection criteria, 24 of them including the cost per QALY gained result as well. The methodological quality of the studies was good (55%) or very good (26%). A total of 124 cost per LYG results were obtained with a mean ratio of 49,529 and a median of 11,490 (standard deviation of 183,080). Since 2003, a commonly accepted Spanish threshold has been referenced by 66% of studies. A significant correlation was found between the cost per LYG and cost per QALY gained results (0.89 Spearman-Rho, 0.91 Pearson). CONCLUSIONS: There is an increasing interest for economic health care evaluations in Spain, and the quality of the studies is also improving. Although a commonly accepted threshold exists, further information is needed for decision-making as well as to identify the relationship between the costs per LYG and per QALY gainedKeywords
This publication has 77 references indexed in Scilit:
- Evaluación económica del uso de pegfilgrastim frente a filgrastim en profilaxis primaria en pacientes con cáncer de mama con riesgo de padecer neutropenia febril en EspañaPharmacoEconomics Spanish Research Articles, 2008
- Análisis coste-efectividad de vareniclina (Champix®) en el tratamiento del tabaquismo en EspañaAnales de Medicina Interna, 2008
- Coste-efectividad del manejo de la hipercolesterolemia familiar con estrategias de tratamiento preventivo basadas en atorvastatinaRevista Espanola de Cardiologia, 2008
- Coste-efectividad de la adición de acarbosa al tratamiento de pacientes con diabetes tipo 2 en EspañaGaceta Sanitaria, 2007
- Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparisonTobacco Control, 2006
- Análisis coste-efectividad del tratamiento intensivo con atorvastatina 80 mg vs. Pravastatina 40 mg en el síndrome coronario agudo: Una evaluación económica basada en el estudio PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy)PharmacoEconomics Spanish Research Articles, 2006
- Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis CJournal of Hepatology, 2005
- Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goalPharmacoEconomics, 2004
- Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in SpainEuropean Journal of Cancer, 2000
- Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart DiseasePharmacoEconomics, 1998